Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1993 1
1994 2
1995 2
1996 3
1997 2
1998 4
1999 3
2000 2
2001 3
2002 1
2003 3
2004 4
2006 4
2007 2
2008 3
2009 3
2010 5
2011 6
2012 5
2013 2
2014 8
2015 5
2016 8
2017 8
2018 10
2019 6
2021 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Results by year

Filters applied: . Clear all
Page 1
Guidelines of care for the management of basal cell carcinoma.
Work Group; Invited Reviewers; Kim JYS, Kozlow JH, Mittal B, Moyer J, Olencki T, Rodgers P. Work Group, et al. Among authors: olencki t. J Am Acad Dermatol. 2018 Mar;78(3):540-559. doi: 10.1016/j.jaad.2017.10.006. Epub 2018 Jan 10. J Am Acad Dermatol. 2018. PMID: 29331385
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ. Choueiri TK, et al. Among authors: olencki t. Eur J Cancer. 2018 May;94:115-125. doi: 10.1016/j.ejca.2018.02.012. Epub 2018 Mar 20. Eur J Cancer. 2018. PMID: 29550566 Free PMC article. Clinical Trial.
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olencki T, Picus J, Small EJ, Dakhil S, George DJ, Morris MJ. Choueiri TK, et al. Among authors: olencki t. J Clin Oncol. 2017 Feb 20;35(6):591-597. doi: 10.1200/JCO.2016.70.7398. Epub 2016 Nov 14. J Clin Oncol. 2017. PMID: 28199818 Free PMC article. Clinical Trial.
Testicular cancer.
Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB; National Comprehensive Cancer Network. Motzer RJ, et al. Among authors: olencki t. J Natl Compr Canc Netw. 2012 Apr;10(4):502-35. doi: 10.6004/jnccn.2012.0050. J Natl Compr Canc Netw. 2012. PMID: 22491049 No abstract available.
Dermatofibrosarcoma protuberans.
Miller SJ, Alam M, Andersen JS, Berg D, Bichakjian CK, Bowen GM, Cheney RT, Glass LF, Grekin RC, Ho AL, Kessinger A, Liegeois N, Lydiatt DD, Michalski J, Morrison WH, Nehal KS, Nelson KC, Nghiem P, Olencki T, Perlis CS, Shaha AR, Tuli M, Urist MM, Wang LC, Zic JA; National Comprehensive Cancer Network. Miller SJ, et al. Among authors: olencki t. J Natl Compr Canc Netw. 2012 Mar;10(3):312-8. doi: 10.6004/jnccn.2012.0032. J Natl Compr Canc Netw. 2012. PMID: 22393193 No abstract available.
Kidney cancer.
Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB; National Comprehensive Cancer Network. Motzer RJ, et al. Among authors: olencki t. J Natl Compr Canc Netw. 2011 Sep 1;9(9):960-77. doi: 10.6004/jnccn.2011.0082. J Natl Compr Canc Netw. 2011. PMID: 21917622 No abstract available.
Merkel cell carcinoma.
Miller SJ, Alam M, Andersen J, Berg D, Bichakjian CK, Bowen G, Cheney RT, Glass LF, Grekin RC, Hallahan DE, Kessinger A, Lee NY, Liegeois N, Lydiatt DD, Michalski J, Morrison WH, Nehal KS, Nelson KC, Nghiem P, Olencki T, Oseroff AR, Perlis CS, Rosenberg EW, Shaha AR, Urist MM, Wang LC; NCCN Merkel Cell Carcinoma Panel. Miller SJ, et al. Among authors: olencki t. J Natl Compr Canc Netw. 2009 Mar;7(3):322-32. doi: 10.6004/jnccn.2009.0024. J Natl Compr Canc Netw. 2009. PMID: 19401064 Free PMC article. No abstract available.
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.
Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker A, Burgess MA, Hanks BA, Olencki T, Kendra K, Church C, Akaike T, Ramchurren N, Shinohara MM, Salim B, Taube JM, Jensen E, Kalabis M, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL. Nghiem P, et al. Among authors: olencki t. J Immunother Cancer. 2021 Apr;9(4):e002478. doi: 10.1136/jitc-2021-002478. J Immunother Cancer. 2021. PMID: 33879601 Free PMC article. Clinical Trial.
A Global Review of Melanoma Follow-up Guidelines.
Trotter SC, Sroa N, Winkelmann RR, Olencki T, Bechtel M. Trotter SC, et al. Among authors: olencki t. J Clin Aesthet Dermatol. 2013 Sep;6(9):18-26. J Clin Aesthet Dermatol. 2013. PMID: 24062870 Free PMC article. Review.
107 results